After excluding 1 tumor with biallelic losses of BARD1, FANCF, and FANCL, and a second tumor with biallelic FANCM loss, 1 of 19 CDK12–/– tumors were CSig3(+) and 3 were iHRD(+); frequencies were not significantly greater compared to the cohort of HRR-Reference tumors (P = 0.69 and P = 1.0, Fisher’s exact test [FES], respectively). Here, BARD1 is linked to neoplasm.